Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Moderate Confidence RCTPrimary source: [Open]
Linked compounds: retatrutide
Outcomes summary
Randomized, placebo-controlled Phase 2 trial evaluating multiple retatrutide dose regimens in adults with obesity; higher doses produced greater weight loss over the treatment period, with gastrointestinal adverse events commonly reported.
Limitations
Phase 2 (not confirmatory), limited duration relative to chronic use, outcomes and tolerability depend on dose-escalation strategy; generalizability depends on enrolled population.
Notes
Primary source: PMID 37366315 (see PubMed link on this page).